NLRP3 and liver dysplastic nodule: NLRP3 inflammasome activation in podocytes accelerates kidney injury in DN (Shahzad et al., 2022), whereas CY-09, a specific NLRP3 inflammasome antagonist, alleviates renal damage in DN by repressing NLRP3 activation (Yang & Zhao, 2022).